Viridian Therapeutics (NASDAQ:VRDN) Cut to Strong Sell at Wall Street Zen

Posted by Brenda Bartman on Oct 7th, 2026

Wall Street Zen cut shares of Viridian Therapeutics (NASDAQ:VRDN – Free Report) from a sell rating to a strong sell rating in a research report released on Sunday,Wall Street Zen reports.

A number of other brokerages have also issued reports on VRDN. Wedbush upped their price target on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Truist Financial lifted their price objective on shares of Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Royal Bank Of Canada boosted their price objective on shares of Viridian Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Tuesday, September 22nd. Needham & Company LLC reissued a “buy” rating and issued a $32.00 target price on shares of Viridian Therapeutics in a research report on Monday, June 29th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $39.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, June 30th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.69.

View Our Latest Stock Analysis on Viridian Therapeutics

Viridian Therapeutics Price Performance

VRDN opened at $18.22 on Friday. Viridian Therapeutics has a 12-month low of $13.18 and a 12-month high of $34.29. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43. The business’s fifty day simple moving average is $21.99 and its 200-day simple moving average is $19.30. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -5.41 and a beta of 1.11.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.02). Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. The business had revenue of $0.28 million for the quarter, compared to analysts’ expectations of $0.06 million. On average, equities research analysts anticipate that Viridian Therapeutics will post -4.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Viridian Therapeutics

In other news, insider Jennifer Tousignant sold 14,212 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total value of $348,194.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in VRDN. Bank of New York Mellon Corp boosted its stake in shares of Viridian Therapeutics by 0.3% during the 1st quarter. Bank of New York Mellon Corp now owns 216,525 shares of the company’s stock worth $4,235,000 after acquiring an additional 659 shares in the last quarter. KBC Group NV bought a new position in shares of Viridian Therapeutics in the 1st quarter valued at approximately $34,000. Integrated Wealth Concepts LLC bought a new position in shares of Viridian Therapeutics in the 2nd quarter valued at approximately $33,000. State of Wyoming acquired a new stake in Viridian Therapeutics in the 2nd quarter worth approximately $43,000. Finally, Arizona State Retirement System lifted its holdings in Viridian Therapeutics by 19.2% in the 2nd quarter. Arizona State Retirement System now owns 21,330 shares of the company’s stock worth $392,000 after purchasing an additional 3,431 shares during the last quarter.

About Viridian Therapeutics

(Get Free Report)

Viridian Therapeutics, Inc (NASDAQ:VRDN) is a clinical-stage biotechnology company focused on developing treatments for autoimmune and inflammatory diseases. The company’s primary research centers on antibody-based medicines designed to target the insulin-like growth factor 1 receptor (IGF-1R), a biological pathway associated with thyroid eye disease (TED).

Viridian’s pipeline includes veligrotug, an investigational monoclonal antibody being developed for TED, as well as additional drug candidates intended to provide alternative dosing options and potentially address broader autoimmune conditions.